Table 2.
Baseline characteristics of patients in severe CIP group.
| Variables | PP group (n=37) | GP group (n=30) | Overall (n=67) | p-value |
|---|---|---|---|---|
| Gender, n (%) | 0.283 | |||
| Male | 34 (91.9%) | 25 (83.3%) | 59 (88.1%) | |
| Female | 3 (8.1%) | 5 (16.7%) | 8 (11.9%) | |
| Age (years) | 0.205 | |||
| ≥65 | 14 (37.8%) | 16 (53.3%) | 30 (44.8%) | |
| <65 | 23 (62.2%) | 14 (46.7%) | 37 (55.2%) | |
| BMI (kg/m2) | 19.8 (15.4, 26.7) | 20.8 (16.0, 27.6) | 20.4 (15.4, 27.6) | 0.070 |
| Smoking history | 0.994 | |||
| Ever smoking | 21 (56.8%) | 17 (56.7%) | 38 (56.7%) | |
| Never smoking | 16 (43.2%) | 13 (43.3%) | 29 (43.3%) | |
| ECOG PS | 0.683 | |||
| ≤2 | 35 (94.6%) | 29 (96.7%) | 64 (95.5%) | |
| 3 | 2 (5.4%) | 1 (3.3%) | 3 (4.5%) | |
| Histological | 0.857 | |||
| Squamous | 14 (37.8%) | 12 (40.0%) | 26 (38.8%) | |
| Adenocarcinoma | 23 (62.2%) | 18 (60.0%) | 41 (61.2%) | |
| Agent | 0.829 | |||
| PD-1 inhibitors | 35 (94.6%) | 28 (93.3%) | 63 (94.0%) | |
| PD-L1 inhibitors | 2 (5.4%) | 2 (6.7%) | 4 (6.0%) | |
| Lines of ICIs | 0.128 | |||
| First line | 28 (75.7%) | 27 (90.0%) | 55 (82.1%) | |
| ≥Second line | 9 (24.3%) | 3 (10.0%) | 12 (17.9%) | |
| PD-L1 expression | 0.362 | |||
| Undetected | 20 (54.1%) | 18 (60.0%) | 38 (56.7%) | |
| Positive | 7 (18.9%) | 8 (26.7%) | 15 (22.4%) | |
| Negative | 10 (27.0%) | 4 (13.3%) | 14 (20.9%) | |
| Distant metastasis | 19 (51.4%) | 18 (60.0%) | 37 (55.2%) | 0.480 |
| Coexisting conditions | ||||
| Combine other irAEs | 6 (16.2%) | 3 (10.0%) | 9 (13.4%) | 0.458 |
| Cardiovascular disease | 9 (24.3%) | 5 (16.7%) | 14 (20.9%) | 0.443 |
| History of prior lung disease | ||||
| COPD | 9 (24.3%) | 4 (13.3%) | 13 (19.4%) | 0.258 |
| Emphysema | 12 (32.4%) | 6 (20.0%) | 18 (26.9%) | 0.254 |
| History of acute radiation pneumonitis | 0 (0%) | 2 (6.7%) | 2 (3.0%) | 0.111 |
Abbreviation: CIP, checkpoint inhibitor related pneumonitis; PP, poor prognosis; GP, good prognosis; BMI, Body Mass Index; ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; PD-1, programmed cell death protein-1; irAEs, Immune-related adverse events; COPD, Chronic obstructive pulmonary disease.